Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Deciphera Pharmaceuticals, Inc. (DCPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results"
02/07/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results"
08/04/2022 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results"
05/04/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results"
08/03/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results"
05/04/2021 8-K Quarterly results
02/09/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results"
08/04/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : May 5, 2020 DECIPHERA PHARMACEUTICALS, INC. Delaware 001-38219 30-1003521 200 Smith Street Waltham, MA 02451 209-6400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act )...",
"Deciphera Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results"
03/09/2020 8-K Quarterly results
11/04/2019 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results"
08/02/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : August 2, 2019 DECIPHERA PHARMACEUTICALS, INC. Delaware 001-38219 30-1003521 500 Totten Pond Road Waltham, MA 02451 209-6400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchang...",
"Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results"
05/09/2019 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results"
03/14/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results"
11/08/2018 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results"
08/07/2018 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results"
05/08/2018 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results"
03/28/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter 2017 Financial Results and Corporate Highlights"
11/14/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy